Sanguine Biosciences collects, processes, and delivers patient biospecimens and relevant health data to support translational and clinical research. The company positions itself as a bridge between patients and researchers to accelerate personalized medicine and cell and gene therapy development. It has supported research at 30 of the top 40 global pharmaceutical and biotechnology companies. Sanguine recently secured $10 million in credit financing to support growth and operations. The company plans to use proceeds to support a newly launched apheresis donation center and to develop cell & gene therapy products derived from apheresis, including GMP‑grade and CD34+ mobilized leukopaks, while funding commercial expansion. Sanguine has received recognition on lists such as the Inc. 5000 and Fortune workplace rankings over the past years. Sanguine provides custom specimen procurement and related laboratory services to biopharmaceutical researchers, with a focus on accelerating precision medicine and cell & gene therapy R&D. In late 2022 the company opened a laboratory in San Diego to provide pre-analytical specimen processing services and launched a new apheresis product family offering large‑volume immune and hematopoietic stem cells from single donors with confirmed disease. Sanguine leverages a nationwide recruitment apparatus and partnerships with patient advocacy groups to access a network of over 60,000 patient donors. The company says it delivered both laboratory services and leukapheresis product offerings late in 2022 and plans to expand those capabilities. Since 2019 Sanguine has grown headcount more than fourfold and revenue threefold while maintaining profitability. The company emphasizes a patients‑first model that supports decentralized and hybrid clinical trial biospecimen collection. Sanguine Biosciences collects and de-identifies patient-derived biospecimens and physician- and self-reported information, generating data sets for researchers involved in drug and biomarker research and discovery. Led by CEO Brian Neman and based in Valencia, CA, the company aggregates biospecimens and associated clinical data and makes those de-identified data available to researchers. The firm intends to use its seed capital to further develop internal infrastructure to efficiently collect, process, document and store samples. Specifically, it plans to scale operations to handle up to 1,000 blood samples per month across the West Coast. The article does not disclose revenue or user metrics. The seed financing was announced on February 23, 2013.

Total raised

$10M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Oct 2023